Taiwan biotech merger signals push into exosome-based therapies
Ever Supreme’s NT$1.7 billion acquisition of Shine Out expands focus from cancer immunotherapy to neurodegenerative diseases
Ever Supreme’s NT$1.7 billion acquisition of Shine Out expands focus from cancer immunotherapy to neurodegenerative diseases



